Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease

NCT04616248 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT04616248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04616248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease
Lead sponsor
University of Southern California
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 9, 2023
Completion date
January 9, 2028
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, basal cell carcinoma, bone sarcoma, cutaneous squamous cell carcinoma, merkel cell carcinoma, metastatic breast carcinoma, metastatic melanoma, prognostic stage iv breast cancer ajcc v8, sarcoma of bone, sarcoma,soft tissue, soft tissue sarcoma, unresectable breast carcinoma, unresectable melanoma